Article Information
History
- February 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Atle Fretheim, (project lead)1,2,*,
- Lars G. Hemkens3,4,5,
- Arnfinn Helleve6,
- Ingeborg Hess Elgersma1,
- Petter Elstrøm1,7 and
- Oliver Kacelnik1,7
- 1Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway
- 2Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway
- 3Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
- 4Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, USA
- 5Meta-Research Innovation Center Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany
- 6Centre for Evaluation of Public Health Interventions, Norwegian Institute of Public Health, Oslo, Norway
- 7Division for Infection Control, Norwegian Institute of Public Health, Oslo. Norway
- ↵*Corresponding author; email: atle.fretheim{at}fhi.no
Posted February 06, 2022.
The GLasses Against transmission of SARS-CoV-2 in the communitY (GLASSY) trial: A pragmatic randomized trial (study protocol)
